A Study to Investigate the Safety and Efficacy of Ricolinostat

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

November 10, 2023

Study Completion Date

November 10, 2023

Conditions

Peripheral Nervous System Diseases

Interventions

DRUG

Ricolinostat

Oral

Trial Locations (1)

Beijing3ERegenacy, Beijing

All Listed Sponsors

lead

Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05229042 - A Study to Investigate the Safety and Efficacy of Ricolinostat | Biotech Hunter | Biotech Hunter